Accelerate your Cell Therapy to Clinic with a Flexible CGMP-Ready Process

This executive summary explores the rapid growth of the cell therapy market and addresses the key challenges faced by sponsors in advancing clinical trials and commercializing therapies. It highlights Catalent’s UpTempo℠ CAR-T Platform, which provides a flexible, scalable, and GMP-compliant manufacturing process to streamline production and regulatory compliance. The platform supports both autologous and allogeneic therapies, offering a customizable solution to meet diverse manufacturing needs while reducing costs and time to market.